The surface of the particle encompasses a layer of T-shaped glycoproteins, each extending up to 10 nm outwards from the envelope, which are important in mediating attachment and entry into host cells.

[citation needed] The Argentinian mammarenavirus genome is composed of two single-stranded RNA molecules, each encoding two different genes in an ambisense orientation.

[citation needed] Since the discovery of Argentinian mammarenavirus in 1958, the geographical distribution of the pathogen, although still confined to Argentina, has expanded.

[citation needed] A potential novel treatment, the NMT inhibitor, has been shown to completely inhibit JUNV infection in cells based assays.

[4] An investigational (in the US) vaccine (Candid1[5]) was developed at the US Army Medical Research Institute for Infectious Disease (USAMRIID)[6] at Ft. Detrick, MD in the 1980s which has shown to be safe, well tolerated and effective in reducing mortality and morbidity due to AHF.

[11] People in laboratories who come in constant contact with Argentinian mammarenavirus are also recommended to take the Junin vaccine to prevent transmission.